Современная ревматология

Расширенный поиск

Эторикоксиб - новый селектавный ингибитор циклооксигеназы 2

Полный текст:


Представлена клиническая характеристика эторикоксиба (Аркоксиа) - нового селективного ингибитора циклооксигеназы 2, обладающего уникальными свойствами, что позволяет выделить его среди других нестероидных противовоспалительных препаратов.


1. <div><p>Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой М.: ГЭОТАР-Медиа, 2008.</p><p>Насонов Е.Л. Нестероидные противовоспалительные препараты (Перспективы применения в медицине). М.: Анко, 2000.</p><p>Camu F., Van Lersberghe C., Lauwers M. Cardiovascular risks and benefits of perioperative nonsteroidal anti-inflammatory drug treatment. Drugs 1992;44(Suppl 5):42-51.</p><p>Phillips D. JCAHO pain standart are unveiled. JAMA 2000; 284: 428-9.</p><p>Clark J. Chronic pain prevalence and analgestic prescribing in a general medical population. J Pain Symp Manag 2002;23:131-7.</p><p>Rainsford K. Anti-inflammatory drugs in the 21st century. Subcell Biochem 2007;42:3-27.</p><p>Zhu K., Devine A., Dick I., Prince R. Association of back pain frequency with mortality, coronary heart events, mobility, and quality of life in elderly women. Spine 2007;32(18):2012-8.</p><p>Alonso-Ruiz A., Pijoan J., Ansuategui E. et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008;9:52.</p><p>Karateev D., Karateev A., Luchikhina L. The need of use of NSAIDs in patients with early and long-standing rheumatoid arthritis. ACR 2008.</p><p>Bombardier C., Laine L., Reicin A. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343(21):1520-8.</p><p>Song I., Poddubnyy D., Rudwaleit M., Sieper J. Benefits and risks of ankylosing spondylitis treatment with nonsteroidal anti-inflammatory drugs. Arthrit Rheum 2008;58(4):929-38.</p><p>Zhang W., Doherty M., Arden N. et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005, 64(4):655-66.</p><p>Jordan K., Arden N., Doherty M. et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62(12):1145-55.</p><p>Schnitzer T., Weaver A., Polis A. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies. J Rheumatol 2005;32:1093-105.</p><p>Pincus T., Koch G., Lei H. et al. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 2004;63:931-9.</p><p>Boureau F., Schneid H., Zeghari N. et al. The IPSO study: ibuprofen, paracetamol study in osteoarthritis. A randomised comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of knee or hip. Ann Rheum Dis 2004;63:1028-35.</p><p>Parr D., Darekar B., Fletcher A., Bulpitt C. Joint pain and quality of life: results of a randomized trial. Br J Clin Pharmacol 1989;27:235-42.</p><p>Pavelka K., Peliskovа Z., Stehlikova H. et al. Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clin Drug Investig 1998;16(6):421-9.</p><p>Beaulieu A., Peloso P., Haraoui B. et al. Once-daily, controlled-release tramadol and sustained-release diclofenac relieve chronic pain due to osteoarthritis: A randomized controlled trial. Pain Res Manag 2008;13(2):103-10.</p><p>Martell B., O'Connor P., Kerns R. et al. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy and association with addiction. Ann Intern Med 2007;146(2):116-27.</p><p>O'Donnell J., Ekman E., Spalding W., McCabe D. Analgesic effectiveness, tolera-bility, and safety of celecoxib versus tra-madol in patients with chronic low back pain. ACR 2007.</p><p>Metscher B., Kь bler U., Jahnel-Kracht H. Dexketoprofen-trometamol and tramadol in acute lumbago. Fortschr Med Orig 2001;118(4):147-51.</p><p>Lee T., Bartle B., Weiss K. Impact of NSAIDS on mortality and the effect of preexisting coronary artery disease in US veterans. Am J Med 2007;120(1):98.</p><p>Goodson N., Brookhart A., Symmons D. et al. Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis 2009;68(3):367-72.</p><p>Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. и др. Применение нестероидных противовоспалительный препаратов. М.: ИМА-ПРЕСС, 2009.</p><p>Simon D., Botting R., Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004;56:387-437.</p><p>Grosser T., Fries S., FitzGerald G. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenes an opportunities. J Clin Invest 2006;16:4.</p><p>Aw T.-J., Haas S., Liew D. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005;165:490-6.</p><p>Matsumoto A., Cavanaugh P. Etoricoxib. Drugs Today 2004;40(5):395-414.</p><p>Patrignani P., Capone M., Tacconelli S. Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. Expert Opin Pharmacother 2003;4(2):265-84.</p><p>Martina S., Vesta K., Ripley T. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother 2005;39(5):854-62.</p><p>Brooks P., Kubler P. Etoricoxib for arthritis and pain management. Ther Clin Risk Manag 2006;2(1):45-57.</p><p>Schwartz J., Dallob A., Larson P. et al. Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects. J Clin Pharmacol 2008;48(6):745-54.</p><p>Malmstrom K., Sapre A., Couglin H. et al. Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. Clin Ther 2004;26(5):667 79.</p><p>Chang D., Desjardins P., King T. et al. The analgesic efficacy of etoricoxib compared with oxycodone/acetaminophen in an acute postoperative pain model: a randomized, double-blind clinical trial. Anesth Analg 2004;99(3):807-15.</p><p>Clarke R., Derry S., Moore R., McQuay H. Single dose oral etoricoxib for acute postoperative pain in adults. Cochrane Database Syst Rev 2009;15(2):CD004309.</p><p>Stephens J., Pashos C., Haider S., Wong J. Making progress in the management of postoperative pain: a review of the cyclooxygenase 2-specific inhibitors. Pharmacotherapy 2004;24(12):1714-31.</p><p>Rasmussen G., Malmstrom K., Bourne M. et al. Etoricoxib provides analgesic efficacy to patients after knee or hip replacement surgery: a randomized, double-blind, placebo-controlled study. Anesth Analg 2005;101(4):1104-11.</p><p>Puura A., Puolakka P., Rorarius M. et al. Etoricoxib premedication for post-operative pain after laparoscopic cholecystectomy. Acta Anaesthesiol Scand 2006;50(6):688-93.</p><p>Liu W., Loo C., Tan H. et al. Comparison of preemptive analgesia efficacy between etoricoxib and rofecoxib in ambulatory gynecological surgery. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2004;26(6):666-70.</p><p>Manyou B., Phupong V. Prospective randomized, double-blinded, placebo-controlled trial of preoperative etoricoxib for pain relief in uterine fractional curettage under paracervical block. Eur J Obstet Gynecol Reprod Biol 2008;140(1):90-4.</p><p>Chau-in W., Thienthong S., Pulnitiporn A. et al. Prevention of post operative pain after abdominal hysterectomy by single dose etoricoxib. J Med Assoc Thai 2008;91(1):68-73.</p><p>Tanprasertkul C., Pongrojpow D. Efficacy of etoricoxib for pain relief during endometrial biopsy; a double blind randomized controlled trial. J Med Assoc Thai 2008;91(1):13-8.</p><p>Smirnov G., Terдvд M., Tuomilehto H. et al. Etoricoxib for pain management during thyroid surgery-a prospective, placebo-controlled study. Otolaryngol Head Neck Surg 2008;138(1):92-7.</p><p>Siddiqui A., Sadat-Ali M., Al-Ghamdi A. et al. The effect of etoricoxib premedication on postoperative analgesia requirement in orthopedic and trauma patients. Saudi Med J 2008;29(7):966-70.</p><p>Schumacher H., Boice J., Dahikh D. et al. Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. BMJ 2002;324:1488-92.</p><p>Rubin B., Burton R., Navarra S. et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthrit Rheum 2004;50(2):598-606.</p><p>Matsumoto A., Melian A., Mandel D. et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 2002;29(8):1623-30.</p><p>Puopolo A., Boice J., Fidelholtz J. et al. A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthrit Cartilage 2007;15(12):1348-56.</p><p>Wiesenhutter C., Boice J., Ko A. et al. Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis. A randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005;80(4):470-9.</p><p>Bingham C. 3rd, Sebba A., Rubin B. et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology 2007;46(3):496-507.</p><p>Moore R., Derry S., McQuay H. Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports. Arthrit Res Ther 2008;10(3):53.</p><p>Van der Heijde D., Baraf H., Ramos-Remus C. et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthrit Rheum 2005;52(4):1205-15.</p><p>Birbara C., Puopolo A., Munoz D. et al. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disabilityРa randomized, placebo-controlled, 3- month trial. J Pain 2003;4(6):307-15.</p><p>Pallay R., Seger W., Adler J. et al. Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial. Scand J Rheumatol 2004;33(4):257-66.</p><p>Zerbini C., Ozturk Z., Grifka J. et al. Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain and disability in patients with chronic low back pain: results of a 4-week, multinational, randomized, double-blind study. Curr Med Res Opin 2005;21(12):2037-49.</p><p>Ramey D., Watson D., Yu C. et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin 2005;21(5):715-22.</p><p>Hunt R., Harper S., Callegari P. et al. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther 2003;17:201-10.</p><p>Watson D., Bolognese J., Yu C. et al. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Curr Med Res Opin 2004;20(12):1899-908.</p><p>Curtis S., Ko A., Bolognese J. et al. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib. Сurr Med Res Opin 2006;22(12):2365-74.</p><p>Laine L., Curtis S.P., Cryer B. et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007;369:465-73.</p><p>Cannon C., Curtis S., FitzGerald G. et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;18:368(9549):1771-81.</p><p>Quercia O., Emiliani F., Foschi F., Stefanini G. Safety of etoricoxib in patients with reactions to NSAIDs. J Investig Allergol Clin Immunol 2008;18(3):163-7.</p><p>Viola M., Quaratino D., Gaeta F. et al. Etoricoxib tolerability in patients with hyper-sensitivity to nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol 2007;143(2):103-8.</p><p>El Miedany Y., Youssef S., Ahmed I., El Gaafary M. Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2006;97(1):105-9.</p></div><br />


Для цитирования:

Каратеев А.Е. Эторикоксиб - новый селектавный ингибитор циклооксигеназы 2. Современная ревматология. 2009;3(2):64-72.

For citation:

Karateev A.E. ETORICOXIB IS A NEW SELECTIVE CYCLOOXYGENASE-2 INHIBITOR. Modern Rheumatology Journal. 2009;3(2):64-72. (In Russ.)

Просмотров: 1520

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)